Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, posted on X:
“API-CAT Study: Extended Reduced-Dose Apixaban for Cancer-Associated VTE
- Apixaban 2.5 mg vs 5.0 mg twice daily for 12m
- Med treat.: 11.8m
- Rec VTE: 2.1% (2.5) vs 2.8% (5.0)
- Bleeding: 12.1% vs 15.6%
- Mortality: 17.7% vs 19.6%.”
“Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.”
Authors: Isabelle Mahé et al.
